Comparing the current results to its competitors, Pyxis Oncology Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.07 %, recorded in the same quarter.
Pyxis Oncology Inc , slower than the average decrease reported by the company's competitors of -72.18 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -72.18 %
Pyxis Oncology Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes multinational biopharmaceutical firms, specialized biotechnology companies, and technologies developed by universities and research institutions. Competitors have developed or are developing product candidates and processes that compete with the company's MICVO product candidate. Globally, there are over 900 antibody-drug conjugates (ADCs) in clinical or preclinical development, primarily for cancer treatment. Specific competitors include Bicara, which is developing an EGFR/TGF-beta targeting bifunctional; Johnson and Johnson, with their EGFR and cMET bispecific antibody amivantamab; and Corbus Pharmaceutical, which is developing the nectin-4 targeting ADC CRB-701, sharing a similar payload (MMAE) and targeting comparable patient populations and clinical timelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Additional competitors include NeoTrail Therapeut, which is developing agents targeting HPV-positive HNSCC.
October 13, 2025
Elucidating the Mechanism of MICVO: Pyxis Oncology s Translational Breakthrough Amidst Competitive Challenges: Pyxis Oncology is at the forefront of unlocking next-generation therapies with their innovative approach to cancer treatment, particularly through the development of Antibody-Drug Conjugates (ADCs). In upcoming medical meetings, Pyxis Oncology will highlight the translational data supporting the mechanism of action for their first-in-concept extracellular-cleaving ADC, micvotabart pelidotin (MICVO). This ADC represents a promising evolution in targeted cancer therapy, addressing the challenges of more conventional approaches. However, amid these scientific advancements, Pyxis Oncology faces competi...
April 25, 2025
: The field of oncology is rapidly evolving with the development of new and innovative treatments. Pyxis Oncology is at the forefront, presenting promising preclinical results for its first-in-concept extracellular-targeting antibody-drug conjugate (ADC), micvotabart pelidotin. This article aims to highlight the significance of this novel ADC s mechanism and performance, amidst Pyxis Oncology s financial challenges in comparison to its competitors. Antibody-drug conjugates (ADCs) have become a pivotal part of targeted cancer therapies, leveraging the specificity of antibodies to deliver cytotoxic agents directly to cancer cells. Micvotabart pelidotin (MICVO), developed by Pyxis Oncology, represents a pion...
November 20, 2024
In recent developments, Pyxis Oncology Inc. has announced promising results from the preliminary clinical data of its candidate drug PYX-201 in a Phase 1 clinical trial. The findings indicate a confirmed overall response rate (ORR) of 50% as per RECIST 1.1, including one complete response among six heavily pretreated patients with head and neck squamous cell carcinoma (HNSCC). Furthermore, the study reported a robust disease control rate of 100%, suggesting that PYX-201 has significant potential as both a monotherapy and in combination with front-line treatment protocols. This sets the stage for planned expansion trials, which are set to initiate dosing in the first quarter of 2025.Despite these encouraging ...
June 28, 2024
Pyxis Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Boston, June 28, 2024 Pyxis Oncology, Inc. (Nasdaq: PYXS)Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to developing next-generation therapeutics aimed at difficult-to-treat cancers, announced today that its Compensation Committee of the Board of Directors granted restricted stock units (RSUs) and stock options to five newly hired employees. The awards were made in compliance with Nasdaq Listing Rule 5635(c)(4) and are designed as an inducement material to new employees joining the company. Inducement Grants BreakdownOn June 28, 2024, Pyxis Oncology s Compensation Committee granted:- Restricted stock...
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Pyxis Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pyxis Oncology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
